• United Therapeutics recently reported that its long-term pivotal phase 3 ADVANCE OUTCOMES trial in pulmonary arterial hypertension met its primary endpoint, with ralinepag cutting the risk of clinical worsening events versus placebo and showing consistent benefits across secondary measures and patient subgroups, while maintaining a safety profile in line with existing prostacyclin therapies.
• This successful trial, coupled with the company’s latest quarterly results showing higher year-on-year sales and net income, positions ralinepag as a potentially important addition to United Therapeutics’ pulmonary hypertension franchise ahead of a planned FDA submission targeted for the second half of 2026.
• We’ll now examine how ralinepag’s phase 3 success could reshape United Therapeutics’ investment narrative, particularly its future growth and pipeline outlook.

The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.

United Therapeutics Investment Narrative Recap

To own United Therapeutics, you have to believe its pulmonary hypertension franchise can keep driving earnings while the pipeline gradually broadens that foundation. The ADVANCE OUTCOMES win reduces a key binary risk around ralinepag and supports the idea that PAH innovation remains central to the story, but it does not remove competitive or pricing pressure on existing prostacyclin products, which, in my view, remains the most important current business risk.

Among recent announcements, the full year 2025 results stand out here: US$3,182.7 million in sales and US$1,334.7 million in net income give United Therapeutics meaningful financial flexibility to fund ralinepag’s path to a planned FDA submission by the second half of 2026. That profit base matters if future PAH competition intensifies or if other late stage programs, like TETON in pulmonary fibrosis, face delays or mixed outcomes.

Yet against the strong PAH data, investors should still be aware of how quickly generic and pricing pressures could start to bite into...

United Therapeutics’ narrative projects $3.7 billion revenue and $1.5 billion earnings by 2028. This requires 6.6% yearly revenue growth and an earnings increase of about $0.3 billion from $1.2 billion today.

Uncover how United Therapeutics' forecasts yield a $572.00 fair value, a 14% upside to its current price.

Exploring Other Perspectives

Before this ralinepag news, the most pessimistic analysts were modeling only about 2.5 percent annual revenue growth to roughly US$3.3 billion and earnings falling to about US$962 million, assuming intensifying patent and pricing risks. If you are comparing that view with the stronger PAH trial result and broader pipeline, it highlights how far opinions can differ and why it is worth looking at several possible futures rather than just one.

Explore 6 other fair value estimates on United Therapeutics - why the stock might be worth 44% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your United Therapeutics research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free United Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate United Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.